Drug intelligence / Profile preview

glucokinase activator

Development stage: Preclinical
Lead developer: Hua Medicine
Modality: Small Molecules
Administration: Oral

Overview

Nucien Pharmaceuticals is developing a small molecule glucokinase (GK) activator for the treatment of Type 2 diabetes. Glucokinase serves as the primary glucose sensor in the body, predominantly expressed in pancreatic beta cells and hepatocytes. By allosterically activating GK, this therapeutic candidate enhances the enzyme's affinity for glucose, thereby stimulating glucose-dependent insulin secretion from the pancreas and increasing glucose uptake and glycogen synthesis in the liver. This dual mechanism of action aims to improve glycemic control in patients with Type 2 diabetes. The program is currently in the preclinical stage of development.

Other names: GK激活剂Glucokinase activator

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on glucokinase activator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glucokinase activator.

Explore the full profile